Sue Washer | Chief Executive Officer |
Susan Schneider | Chief Medical Officer |
Jon Lieber | Chief Financial Officer |
Joe Pantginis | H.C. Wainright |
Dae Gon Ha | Stifel |
Yanan Zhu | Wells Fargo |
Kristen Kluska | Cantor Fitzgerald |
Yun Zhong | BTIG |
Zegbeh Jallah | ROTH Capital |
Good morning, and welcome to the AGTC Financial Results Conference Call for the Second Quarter of Fiscal year 2022. Today's call is being recorded.
Before we get started, I would like to remind everyone that during this call, AGTC may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about the timing and outcomes from data expected in its SKYLINE and VISTA trials and the type of data that may support registration and potential approval. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic and the other risks described in the Risk Factors section of AGTC's most recent filed annual report on Form 10-K and other periodic reports filed with the SEC. AGTC undertakes no obligation to update any forward-looking statements after the date of this call.